<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-02-10">10 February 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Charles</forename><surname>Peterfy</surname></persName>
							<email>charles.peterfy@spiresciences.com</email>
							<affiliation key="aff1">
								<orgName type="institution">Spire Sciences, Inc</orgName>
								<address>
									<settlement>Boca Raton, Florida</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerd</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité-University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vivian</forename><forename type="middle">P</forename><surname>Bykerk</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Rheumatology, Hospital for Special Surgery</orgName>
								<orgName type="institution">Weill Cornell Medical College</orgName>
								<address>
									<settlement>New York</settlement>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernard</forename><forename type="middle">G</forename><surname>Combe</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Rheumatology</orgName>
								<address>
									<addrLine>Service d&apos;Immuno-Rheumatologie</addrLine>
									<settlement>Montpellier</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julie</forename><forename type="middle">C</forename><surname>Dicarlo</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Spire Sciences, Inc</orgName>
								<address>
									<settlement>Boca Raton, Florida</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of California Los Angeles</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tom</forename><forename type="middle">W J</forename><surname>Huizinga</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Leiden University Medical Center</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dennis</forename><forename type="middle">A</forename><surname>Wong</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Bristol-Myers Squibb</orgName>
								<address>
									<settlement>Princeton</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philip</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution">University of Leeds</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">NIHR Leeds Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit2">Leeds Teaching Hospitals NHS Trust</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Emery</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution">University of Leeds</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">NIHR Leeds Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit2">Leeds Teaching Hospitals NHS Trust</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Spire Sciences, Inc</orgName>
								<address>
									<addrLine>5314 Boca Marina Cir N</addrLine>
									<postCode>33487-5221</postCode>
									<settlement>Boca Raton</settlement>
									<region>FL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-02-10">10 February 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">A57DE703C94AAB3E2FA70B6E15557C7B</idno>
					<idno type="DOI">10.1136/annrheumdis-2015-208258</idno>
					<note type="submission">Received 16 July 2015 Revised 30 November 2015 Accepted 16 January 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough</term>
					<term>travel support: Abbott Laboratories, Roche. DAW: shareholder and former employee of Bristol-Myers Squibb. PGC: speakers bureau or consultancies: AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Roche. PE: consulting fees: AbbVie, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Roche, Samsung, Takeda, UCB</term>
					<term>grant/research support: AbbVie, Merck, Pfizer, Roche</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission or low disease activity.</s><s>Methods Patients with early, active RA were randomised to ABA plus methotrexate (ABA/MTX) 125 mg/week, ABA 125 mg/week or MTX for 12 months.</s><s>All RA treatments were withdrawn after 12 months in patients with DAS28 (C reactive protein (CRP)) &lt;3.2.</s><s>Adjusted mean changes from baseline in MRI-based synovitis, osteitis and erosion were calculated for the intention-to-treat population.</s><s>Results 351 patients were randomised and treated: ABA/MTX (n=119), ABA (n=116) or MTX (n=116).</s><s>Synovitis and osteitis improved, and progression of erosion was statistically less with ABA/MTX versus MTX at month 12 (−2.35</s><s>vs −0.68, −2.58 vs −0.68, 0.19 vs 1.53, respectively; p&lt;0.01 for each) and month 18 (−1.34</s><s>vs −0.49</s><s>−2.03 vs 0.34, 0.13 vs 2.0, respectively; p&lt;0.01 for erosion); ABA benefits were numerically intermediate to those for ABA/MTX and MTX.</s><s>Conclusions Structural benefits with ABA/MTX or ABA may be maintained 6 months after withdrawal of all treatments in patients who have achieved remission or low disease activity.</s><s>Trial registration number NCT01142726; Results.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Abatacept is a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)-immunoglobulin G1 fusion protein <ref type="bibr" target="#b7">1</ref> that selectively modulates the CD80/ CD86:CD28 costimulatory pathway required for T-cell activation. <ref type="bibr" target="#b8">2</ref> In people with rheumatoid arthritis (RA), treatment with abatacept has been shown to normalise levels of many inflammatory mediators associated with disease activity and progression. <ref type="bibr" target="#b7">1</ref></s><s>he Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial evaluated clinical remission at 12 months with subcutaneous abatacept plus methotrexate (MTX), abatacept monotherapy or MTX alone in patients with early RA and maintenance of remission following rapid withdrawal of all RA treatments. <ref type="bibr" target="#b9">3</ref></s><s>Patients treated with abatacept in combination with MTX achieved higher rates of protocol-defined Disease Activity Score (DAS) remission (DAS28 C reactive protein (CRP) &lt;2.6) versus MTX alone, and a small but significantly higher number of patients achieved sustained DAS-defined remission following withdrawal of all RA treatments. <ref type="bibr" target="#b9">3</ref></s><s>The safety profile of abatacept, in combination with MTX or as monotherapy, was comparable with that of MTX alone. <ref type="bibr" target="#b9">3</ref></s><s>he AVERT trial evaluated clinical and also MRI outcomes.</s><s>6]<ref type="bibr" target="#b13">[7]</ref> In patients with established RA, the benefits of abatacept in reducing synovitis and osteitis have previously been demonstrated using MRI. <ref type="bibr">8 9</ref></s><s>n this substudy of the AVERT trial, we report MRI measures of disease in patients with DAS-defined remission (DAS28 (CRP) &lt;2.6) following 12 months of treatment and subsequent withdrawal of all RA medication, for up to 18 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and patient population</head><p><s>The trial design and primary results for AVERT (NCT01142726) have been described previously. <ref type="bibr" target="#b9">3</ref></s><s>riefly, patients were randomised (1:1:1) to receive abatacept 125 mg/week plus MTX, abatacept monotherapy (125 mg/week) or MTX alone for 12 months.</s><s>At month 12, patients with DAS28 (CRP) &lt;3.2 could enter the withdrawal period and all treatments for RA were stopped, with MTX and corticosteroids being tapered during the first month.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p><s>All patients underwent contrast-enhanced 1.5 T MRI of the clinically most active wrist and hand (metacarpophalangeal joints 1-5) at baseline and at 6-month intervals thereafter; the same wrist/hand was imaged at each designated visit (see online supplementary material).</s><s>MRI assessments were evaluated at baseline and up to month 18; only patients with baseline and postbaseline MRI assessments were included (see online supplementary material).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Adjusted mean changes from baseline in MRI scores for synovitis, osteitis and erosion were calculated at months 12 and 18 in the intention-to-treat population, and analysed using a longitudinal repeated measures model adjusting for MRI score and corticosteroid use (yes/no) at baseline and presented by treatment group; observed data at all time points were included.</s><s>For all mean response rates, SE, 95% CIs and p values were calculated (see online supplementary material).</s></p><p><s>The proportion of patients achieving DAS-defined remission and MRI non-progression (defined as change from baseline ≤smallest detectable change separately for erosion, osteitis and synovitis) was calculated at months 6, 12 and 18 as an exploratory endpoint (see online supplementary material).</s><s>The percentage change in CRP from baseline was evaluated over time.</s><s>Additionally, post hoc analyses included the number of patients achieving DAS-defined remission and MRI progression (defined as change from baseline &gt;smallest detectable change) at month 18; the proportion of patients with a synovitis score &gt;5 at baseline and at months 6, 12 and 18; and adjusted mean changes from baseline in MRI scores in the subgroup of patients who had DAS28 (CRP) &lt;2.6 at both months 12 and 18.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient disposition and baseline characteristics</head><p><s>A total of 511 patients were enrolled, and 351 patients at 72 worldwide sites were randomly assigned (1:1:1) to treatment with abatacept plus MTX (n=119), abatacept monotherapy (n=116) or MTX (n=116).</s><s>The proportion of patients with MRI assessments at baseline was 95.8% (114/119), 96.6% (112/ 116) and 95.7% (111/116), respectively; at baseline and month 12, it was 76.5% (91/119), 69.8% (81/116) and 72.4% (84/ 116), respectively; and at baseline, month 12 and month 18, it was 31.9% (38/119), 30.2% (35/116) and 25.0% (29/116), respectively.</s><s>The average rate of missing MRI scores for those who had assessments at baseline was 16.9% over 12 months and 69.9% at 18 months.</s><s>A total of 129/202 patients (63.9%) who entered the withdrawal period and who had MRI assessments at baseline and at month 12 discontinued during the withdrawal period (abatacept plus MTX, n=48 (37.2%); abatacept monotherapy, n=40 (31.0%);</s><s>MTX, n=41 (31.8%)).</s><s>The main reason for discontinuation was lack of efficacy (n=123/202; 60.9%).</s><s>Clinical baseline characteristics for patients with MRI assessments at baseline and at month 12 were similar across treatment groups and were comparable with the overall AVERT population (table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p><s>Abatacept plus MTX resulted in significantly greater decreases from baseline in synovitis and osteitis scores on-treatment, and significantly less progression of erosion score on-treatment and following withdrawal of all therapies than MTX alone (figure <ref type="figure" target="#fig_0">1</ref>).</s><s>While mean MRI synovitis and osteitis scores increased following withdrawal of treatment in all three groups, the adjusted mean reductions from baseline with abatacept plus MTX at month 18 were still numerically greater than those with MTX alone (figure <ref type="figure" target="#fig_0">1A, B</ref>).</s><s>Changes in erosion score showed minimal difference between months 6 and 18 (figure <ref type="figure" target="#fig_0">1C</ref>).</s><s>Benefits of abatacept monotherapy were numerically intermediate to those of abatacept plus MTX and MTX alone.</s><s>Cumulative probability plots for changes in MRI scores from baseline at month 12 are shown in online supplementary figure S1.</s></p><p><s>During study treatment, there was a reduction in the proportion of patients with active synovitis (score &gt;5; indicative of active disease resulting in erosion progression <ref type="bibr" target="#b16">10</ref> ) in the abatacept plus MTX group versus that in the MTX alone group; at month 18, there was a numerical increase versus MTX alone (see online supplementary figure <ref type="figure" target="#fig_0">S1</ref>).</s></p><p><s>During study treatment, a statistically higher percentage of patients receiving abatacept plus MTX achieved DAS-defined remission together with MRI non-progression in synovitis, osteitis and erosion compared with those receiving MTX alone (table <ref type="table" target="#tab_1">2</ref>).</s><s>Fewer patients in all three treatment groups achieved DAS-defined remission together with MRI non-progression after withdrawal of study drug compared with on-treatment (table <ref type="table" target="#tab_1">2</ref>).</s><s>However, the percentages of patients in the abatacept plus MTX group were still approximately twice those of the MTX-alone group.</s><s>The effect of abatacept monotherapy was numerically intermediate to that of abatacept plus MTX and MTX alone.</s><s>In all treatment groups, a small number of patients still had MRI progression (see online supplementary material).</s></p><p><s>Post hoc analyses revealed that, in the small proportion of patients with DAS-defined remission at both months 12 and 18, MRI benefits achieved at month 12 were maintained up to month 18 (ie, after withdrawal of all therapies) in all three groups (see online supplementary figure <ref type="figure">S3</ref>).</s></p><p><s>Abatacept plus MTX treatment resulted in greater decreases from baseline in the inflammatory marker, CRP, during the treatment period and following the withdrawal of all therapies compared with MTX alone.</s><s>Abatacept monotherapy and MTX alone had similar effects on CRP (see online supplementary table <ref type="table" target="#tab_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In this analysis of tissue effects, abatacept reduced inflammation and structural damage progression as assessed by changes in MRI scores (synovitis, osteitis and bone erosions) in patients with early and progressive RA.</s><s>Following withdrawal of all therapies in patients with clinical disease activity, there was some reappearance of inflammatory activity in the joints.</s><s>However, in those patients who maintained clinical remission or low disease activity following withdrawal of all RA therapy, this remission/ low disease activity correlated with maintenance of inflammation control and structural benefits irrespective of initial treatment group.</s><s>During both the treatment and withdrawal periods, improvements as assessed by MRI were greatest for abatacept plus MTX, followed by abatacept monotherapy and MTX monotherapy.</s></p><p><s>3]<ref type="bibr" target="#b20">[14]</ref><ref type="bibr" target="#b21">[15]</ref><ref type="bibr" target="#b22">[16]</ref> The data presented here are also consistent with the maintenance of MRI benefits for 6 months following the withdrawal of abatacept in patients with early RA reported in the ADJUST trial. <ref type="bibr" target="#b15">9</ref></s><s>Only a few studies of biologics have evaluated treatment withdrawal or de-escalation and imaging outcomes (MRI or radiography) in patients with RA. <ref type="bibr" target="#b23">[17]</ref><ref type="bibr" target="#b24">[18]</ref><ref type="bibr" target="#b25">[19]</ref><ref type="bibr" target="#b26">[20]</ref> Consistent with our study, Smolen et al showed that most patients with early RA (&lt;1 year disease duration) who achieved a stable low-dose disease activity target at ∼6 months maintained structural benefits, despite withdrawal of adalimumab.</s><s>]<ref type="bibr" target="#b25">[19]</ref><ref type="bibr" target="#b26">[20]</ref> Some limitations of the present study should be taken into account.</s><s>The post hoc analysis of change from baseline in MRI scores in patients with DAS28 (CRP) &lt;2.6 at both months 12 and 18 had a small sample size, and therefore additional studies are needed to confirm these results, despite the sensitivity of MRI for detecting change.</s><s>Additionally, the study was not powered to compare abatacept combination therapy with monotherapy.</s></p><p><s>In conclusion, these data from the AVERT study demonstrate that abatacept reduces inflammation and structural damage progression as assessed by MRI, and extends the current understanding of the effect of abatacept on synovium and bone.</s><s>The withdrawal of abatacept therapy after achieving remission in some patients with early, progressive RA appears to be possible without an associated risk of joint damage progression.</s></p><p><s>Contributors CP and PGC contributed to the MRI study design and data acquisition/interpretation.</s><s>GRB, VPB, BGC, DEF, TWJH and PE contributed to data acquisition and interpretation.</s><s>JCD and DAW contributed to data analysis and interpretation.</s><s>All authors assisted in the drafting and critical revision of the manuscript and agree to be accountable for all aspects of the work.</s></p><p><s>Funding The study was funded by Bristol-Myers Squibb.</s></p><p><s>Competing interests CP: consulting fees: AbbVie, Acerta, Amgen, AstraZeneca, Bristol-Myers Squibb, Centrexion, Daiichi Sankyu, Five Prime Therapeutics, Genentech, Hoffmann-La Roche, Janssen, Lilly USA, MedImmune, Merck, Novartis, Plexxikon, Pfizer, Sanofi, Salix-Santarus, Samsung; speakers bureau: Amgen; Founder and CEO of Spire Sciences, which provides imaging services to multiple pharmaceutical companies.</s><s>GRB: grant/research support: Bristol-Myers Squibb, AbbVie, Pfizer, MedImmune, Novartis, Roche, UCB, Lilly; consultant: Bristol-Myers Squibb, AbbVie, Pfizer, MSD, MedImmune, Roche, UCB; speakers bureau: Bristol-Myers Squibb, AbbVie, Pfizer, MSD, Roche, UCB.</s><s>VPB: Consultant: Amgen, Antares, Bristol-Myers Squibb, Genentech, Pfizer, UCB.</s><s>BGC: grant/research support: Pfizer, Roche-Chugai, UCB; speakers bureau: Bristol-Myers Squibb, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai, UCB.</s><s>JCD: consulting: AbbVie, Acerta, Amgen, AstraZeneca, Bristol-Myers Squibb, Centrexion, Daiichi Sankyu, Five Prime Therapeutics, Genentech, Hoffmann-La Roche, Janssen, Lilly USA, MedImmune, Merck, Novartis, Plexxikon, Pfizer, Sanofi, Salix-Santarus, Samsung; Employee of Spire Sciences, Inc., which provides imaging services to multiple pharmaceutical companies.</s><s>DEF: grant/research support: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB; consultant: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB; speakers bureau (CME only): AbbVie, Actelion, UCB.</s><s>TWJH: consulting fees: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Crescendo Bioscience, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Roche, Sanofi-Aventis, Schering-Plough, UCB, Inc., Eli Lilly; non-remunerative positions of influence: Meteor Board; research grants: EU &amp; Dutch Arthritis</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Adjusted mean change from baseline in MRI scores (ITT population).</s><s>Change from baseline in (A) synovitis scores, (B) osteitis and (C) erosion at 6, 12 and 18 months.</s><s>*p&lt;0.05,</s><s>**p&lt;0.01 and ***p&lt;0.001</s><s>for adjusted mean difference versus MTX at given time point.</s><s>Error bars represent SEs.</s><s>ITT, intention-to-treat; MTX, methotrexate.</s></p></div></figDesc><graphic coords="3,87.65,48.42,419.98,527.13" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics for patients with MRI assessments at baseline and month 12</s></p></div></figDesc><table><row><cell></cell><cell>Abatacept plus</cell><cell>Abatacept</cell><cell>MTX</cell></row><row><cell>Characteristic</cell><cell>MTX (n=91)</cell><cell>monotherapy (n=81)</cell><cell>(n=84)</cell></row><row><cell>Synovitis score</cell><cell>5.6 (4.2)</cell><cell>5.3 (3.8)</cell><cell>5.7 (4.2)</cell></row><row><cell>Osteitis score</cell><cell>4.4 (6.9)</cell><cell>4.3 (6.7)</cell><cell>3.4 (6.4)</cell></row><row><cell>Erosion score</cell><cell>7.2 (7.0)</cell><cell>5.1 (4.7)</cell><cell>6.3 (7.8)</cell></row><row><cell>Symptom duration,</cell><cell>0.6 (0.5)</cell><cell>0.6 (0.5)</cell><cell>0.5 (0.5)</cell></row><row><cell>years</cell><cell></cell><cell></cell><cell></cell></row><row><cell>DAS28 (CRP)</cell><cell>5.5 (1.3)</cell><cell>5.5 (1.2)</cell><cell>5.3 (1.3)</cell></row><row><cell>HAQ-DI</cell><cell>1.5 (0.7)</cell><cell>1.4 (0.6)</cell><cell>1.4 (0.6)</cell></row><row><cell>Tender Joint Count</cell><cell>13.8 (7.8)</cell><cell>14.3 (7.7)</cell><cell>12.5 (7.7)</cell></row><row><cell>(28 joints)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Swollen Joint Count</cell><cell>11.2 (7.1)</cell><cell>12.4 (7.6)</cell><cell>10.2 (6.9)</cell></row><row><cell>(28 joints)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CRP, mg/L</cell><cell>17.5 (23.2)</cell><cell>16.6 (25.6)</cell><cell>16.0 (21.2)</cell></row><row><cell cols="2">Data are presented as mean (SD).</cell><cell></cell><cell></cell></row><row><cell cols="4">CRP, C reactive protein; DAS, Disease Activity Score; HAQ-DI, Health Assessment</cell></row><row><cell cols="3">Questionnaire-Disability Index; MTX, methotrexate.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Proportion of patients with DAS28 (CRP) remission and MRI non-progression per MRI pathology over time(ITT population)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="3">Patients with DAS28 (CRP) remission* and MRI</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>non-progression †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Abatacept plus MTX vs</cell><cell>Abatacept monotherapy vs</cell></row><row><cell></cell><cell>Study time</cell><cell></cell><cell>Abatacept</cell><cell></cell><cell>MTX estimate of</cell><cell>MTX estimate of</cell></row><row><cell></cell><cell>point</cell><cell>Abatacept plus</cell><cell>monotherapy</cell><cell></cell><cell>difference</cell><cell>difference</cell></row><row><cell>MRI pathology</cell><cell>(months)</cell><cell>MTX (n=119)</cell><cell>(n=116)</cell><cell>MTX (n=116)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell>Synovitis-n ‡ (%)</cell><cell>6</cell><cell>44 (37.0)</cell><cell>32 (27.6)</cell><cell>28 (24.1)</cell><cell>12.84 (0.33 to 25.34);</cell><cell>3.45 (−8.67 to 15.57);</cell></row><row><cell>(95% CI) §</cell><cell></cell><cell>(28.30 to 45.65)</cell><cell>(19.45 to 35.72)</cell><cell>(16.35 to 31.93)</cell><cell>p=0.046</cell><cell>p=0.653</cell></row><row><cell></cell><cell>12</cell><cell>59 (49.6)</cell><cell>43 (37.1)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>(40.60 to 58.56)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2015-208258 on 10 February 2016. Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The first draft of the manuscript was prepared by academic and industry authors, with professional medical writing and editorial assistance provided by Stacey Reeber, PhD, at Caudex and funded by Bristol-Myers Squibb.</s><s>The academic authors vouch for the completeness and accuracy of the data and data analyses, and for the fidelity of the study to the protocol.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">†MRI non-progression was defined as change from baseline ≤smallest detectable change. Smallest detectable change values used for non-progression: synovitis (2.01), osteitis (2.81) and erosion (2.29). ‡n=number of patients with DAS28 (CRP) remission and MRI non-progression</title>
		<author>
			<persName><forename type="first">*</forename><surname>Das-</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">defined remission was defined as DAS28 (CRP) &lt;2.6</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">§Normal approximation is used if the number of DAS28 (CRP) remission and MRI non-progression for all treatment arms was at least 5; otherwise an exact method was used</title>
	</analytic>
	<monogr>
		<title level="j">CRP, C</title>
		<imprint/>
	</monogr>
	<note>reactive protein</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">DAS, Disease Activity Score</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Methotrexate</forename><surname>Mtx</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Peterfy</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-208258</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1501" to="1505" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-208258on10</idno>
		<imprint>
			<date type="published" when="2016-02">February 2016</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Abatacept mechanism of action: concordance with its clinical profile</title>
		<author>
			<persName><forename type="first">G</forename><surname>Herrero-Beaumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martínez</forename><surname>Calatrava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Castañeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.reuma.2011.08.002</idno>
	</analytic>
	<monogr>
		<title level="j">Reumatol Clin</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="78" to="83" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">CD28/B7 system of T cell costimulation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lenschow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Walunas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bluestone</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev.immunol.14.1.233</idno>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="233" to="258" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Bykerk</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-206106</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="19" to="26" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Imaging in early rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Mcqueen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.berh.2013.09.005</idno>
	</analytic>
	<monogr>
		<title level="j">Best Pract Res Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="499" to="522" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Mcqueen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Benton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Perry</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.11162</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1814" to="1827" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hetland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ejbjerg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hørslev-Petersen</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.088245</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="384" to="390" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ostergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-203444</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1968" to="1974" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Durez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Alten</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-201611</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1287" to="1294" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Durez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.119016</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="510" to="516" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gandjbakhch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Haavardsholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.131088</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="398" to="406" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mease</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gladstein</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.30176</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="939" to="948" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Decreased incidence of synovitis, osteitis, and erosion in early RA patients treated with adalimumab plus methotrexate compared to those with methotrexate alone: high-field MRI analysis from OPTIMA (Abstract 123)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Peterfy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Haraoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Durez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page">S51</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Østergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.30592</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="3712" to="3722" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Peterfy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Olech</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204762</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="810" to="816" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Peterfy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Tak</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-206015</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="170" to="177" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging substudy in a phase 2b dose-ranging study of baricitinib, an oral janus kinas 1/janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Peterfy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Genovese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">1050</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(13)61751-1</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="page" from="321" to="332" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename></persName>
		</author>
		<idno type="DOI">10.1002/art.20712</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="27" to="35" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Sustained remission with etanercept tapering in early rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hammoudeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Fitzgerald</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1316133</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1781" to="1792" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Detert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bastian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-201612</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="844" to="850" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
